



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
May 6, 2022
9 A.M. EDT

Virtual Meeting - Microsoft Teams Link Provided Below

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of February 4, 2022
4. Preferred Drug List: Therapeutic Class Re-Review
 - a) CNS and Others
 - i. Agents for the Treatment of Opiate Addiction
 - ii. Antiemetic/Antivertigo Agents
 - iii. Antiseizure Agents
 - iv. Gastroprotective NSAIDs
 - v. Movement Disorder Agents
 - vi. Narcotic Antitussive/1st Generation Antihistamine Combinations
 - vii. Narcotics
 - viii. Skeletal Muscle Relaxants
 - ix. Smoking Deterrent Agents
 - b) Dermatologic Agents
 - i. Acne Agents
 - ii. Antipsoriatic Agents
 - c) Endocrine



- i. Anaphylaxis Agents
 - ii. Bone Formation Stimulating Agents
 - iii. Bone Resorption Inhibitors
 - iv. DPP4 Inhibitors and Combination Agents
 - v. GLP-1 Receptor Agonists and Combinations
 - vi. Glucagon Agents
 - vii. Growth Hormones
 - viii. Injectable Hypoglycemics, Insulin
 - ix. Miscellaneous Oral Antidiabetic Agents
 - x. SGLT2 Inhibitors and Combinations
 - xi. Testosterones
- d) Estrogen and Related Agents
- i. Estrogen and Related Agents
- e) Gastrointestinal Agents
- i. Anti-ulcer Agents
 - ii. *H. Pylori* Agents
 - iii. H2 Receptor Antagonists
 - iv. Laxatives and Cathartics
 - v. Pancreatic Enzymes
 - vi. Proton Pump Inhibitors
 - vii. Ulcerative Colitis Agents
- f) Genitourinary Agents
- i. Benign Prostatic Hypertrophy Agents
 - ii. Urinary Tract Antispasmodic/Anti-Incontinence Agents
- g) Hematologic Agents
- i. Direct Factor Xa Inhibitors
 - ii. Direct Thrombin Inhibitors
 - iii. Hematinics
 - iv. Heparin and Related Products
 - v. Leukocyte (WBC) Stimulants
 - vi. Platelet Aggregation Inhibitors
- h) Targeted Immunomodulators

- i) Topical Agents
 - i. Miotics-Intraocular Pressure Reducers
 - ii. Ophthalmic Antihistamines
 - iii. Ophthalmic Anti-Inflammatory Agents
 - iv. Ophthalmic Mast Cell Stabilizers
 - v. Otic Preparations
 - vi. Treatments of Xerophthalmia (dry eye)
 - vii. Topical Anti-Inflammatory Agents-NSAIDs
 - viii. Topical Antiparasitics
 - ix. Topical Immunomodulators
 - x. Topical Postherpetic Neuralgia Agents
- 5. New Business
- 6. Public Comment
- 7. Other Business
- 8. Adjourn

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

https://teams.microsoft.com/l/meetup-join/19%3ameeting_MzYzMmUwNTktOTlIZi00OWY0LThhMDctNWZkMjAwYzNlZWU2%40thread.v2/0?context=%7b%22Tid%22%3a%22db05faca-c82a-4b9d-b9c5-0f64b6755421%22%2c%22Oid%22%3a%2253df74d0-e68c-46fe-81f5-fac4b0bd8ef8%22%7d

Join with a video conferencing device

425899727@t.plcm.vc

Video Conference ID: 119 888 828 9

[Alternate VTC instructions](#)

Or call in (audio only)

[+1 952-222-7450,,282344689#](#) United States, Bloomington

Phone Conference ID: 282 344 689#